Cleared Traditional

TOTAL RADIOIMMUNOASSAY KIT (K821101) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K821101 · Bioclinical Group · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1982
Decision
15d
Days
Class 2
Risk

K821101 is an FDA 510(k) clearance for the TOTAL RADIOIMMUNOASSAY KIT. Classified as Radioimmunoassay, Total Thyroxine (product code CDX), Class II - Special Controls.

Submitted by Bioclinical Group (Walker, US). The FDA issued a Cleared decision on May 5, 1982 after a review of 15 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1700 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Bioclinical Group devices

Submission Details

510(k) Number K821101 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 20, 1982
Decision Date May 05, 1982
Days to Decision 15 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
73d faster than avg
Panel avg: 88d · This submission: 15d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CDX Radioimmunoassay, Total Thyroxine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1700
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CDX Radioimmunoassay, Total Thyroxine

All 33
Devices cleared under the same product code (CDX) and FDA review panel - the closest regulatory comparables to K821101.
IQ T4 IMMUNOASSAY
K864560 · Bd Becton Dickinson Vacutainer Systems Preanalytic · Dec 1986
COAT-A-COUNT NEONATAL T4 KIT RIA KIT
K831107 · Diagnostic Products Corp. · May 1983
MONOCLONAL ANTIBODY T4 RADIO-KIT
K823265 · Bd Becton Dickinson Vacutainer Systems Preanalytic · Dec 1982
QUANTAPHASE T-4 RIA
K811787 · Bio-Rad · Jul 1981
COAT-A-COUNT T4 RIA KIT
K811315 · Diagnostic Products Corp. · May 1981
RIA PHASE T4
K800203 · Boehringer Mannheim Corp. · Mar 1980